Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase ib, open-label, randomized, dose-finding, multicenter study to evaluate the safety, pharmacokinetics, and efficacy of GDC-8264 in combination with standard of care in the treatment of acute graft-versus-host disease in patients who have undergone allogeneic hematopoietic stem cell transplantation

Next Previous
Search
Trial Profile

A phase ib, open-label, randomized, dose-finding, multicenter study to evaluate the safety, pharmacokinetics, and efficacy of GDC-8264 in combination with standard of care in the treatment of acute graft-versus-host disease in patients who have undergone allogeneic hematopoietic stem cell transplantation

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RG 6287 (Primary) ; Methylprednisolone; Prednisone
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Genentech

Most Recent Events

  • 29 Jan 2024 Status changed from recruiting to discontinued, due to business reasons. There were no safety or efficacy concerns regarding the study or study drug in the decision to terminate the study.
  • 06 Apr 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 31 Mar 2023 to 30 Apr 2023.
  • 02 Mar 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 28 Feb 2023 to 31 Mar 2023.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top